Skip to content
AnalystLens

GE HealthCare Technologies Inc.GEHC

Sector
Other
Industry
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Exchange
Nasdaq

Stock Price $GEHC

Latest filings

You are here#38 of 40 in Healthcare by market cap

Filing record · 2022–202610-K410-Q118-K55

GEHC filed 4 annual reports (10-K), 11 quarterly reports (10-Q) and 55 current reports (8-K) between 2022 and 2026.

  1. FY2022 annual report10-K · Feb ’23Feb ’23
  2. Leadership change8-K · Apr ’24Apr ’24
  3. Leadership change8-K · Mar ’26Mar ’26

01—Key figures

Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  5. $20.63B
YoY changeLargest recent move+6.6%in FY23Latest +4.8%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →
All GEHC Financial Metrics56 metrics

Income Statement13

Balance Sheet25

Cash Flow13

Per Share5

02—Overview

GE HealthCare Technologies Inc. Financial Overview 2022–2025

Updated Aug 8, 2026

GE HealthCare's Pharmaceutical Diagnostics segment surged with a striking 15.6% revenue increase in FY2025, driving overall growth despite deep headwinds in the Chinese market. Since separating from its parent conglomerate, the business has successfully transitioned into a resilient standalone entity that offsets regional volatility through targeted acquisitions and aggressive pricing adjustments.

The company expanded steadily as an independent operation, with total revenue growing from $18.34 billion in FY2022 to $20.625 billiona in FY2025. This long-term trajectory was fueled by strategic deals, most notably the $2.3 billion acquisition of Intelerad and the buyout of Nihon Medi-Physics. While regional challenges caused China sales to plummet 15% in FY2024, management mitigated this drag by tightening expenses and recovering $107 million in tariff refunds by Q2 2026. As a result, operating income climbed 5.3% to reach $2.763 billion in FY2025, even as total debt swelled to $10.003 billion to fund the strategic investments.

Management actively returned capital to shareholders amidst this operational reorganization, executing $200 millionb in buybacks under a new $1 billion share repurchase program. The market rewarded this balanced approach to growth and profitability; GE HealthCare traded at an 18.0x P/E ratio and closed at $82.02 per share at the end of FY2025.

Recent Developments (Q1 and Q2 2026)

GE HealthCare reorganized in Q2 2026, combining its Imaging and Advanced Visualization units into the Advanced Imaging Solutions segment. Total revenue reached $5.3 billionc for the quarter, a 5.7% year-over-year increase supported by 7.9% growth in this division. Earlier in Q1 2026, operating margin compressed by 310 basis points and operating income fell 18.2% to $515 million due to cost inflation. Executive leadership shifted when CFO Jay Saccaro resigned, effective August 14, 2026.

Bulls will emphasize the bottom-line rebound in Q2 2026, where net income grew 15.5% to $561 milliond and first-half free cash flow increased 70.0% to $180 million. Bears can point to fulfillment issues in the Patient Care Solutions segment, which suffered a 13.3% revenue decline. Trading at a 13.8x P/E ratio as of July 29, 2026, the stock appears cheaply valued relative to this earnings recovery.

What to watch: the permanent CFO search; stabilization of Patient Care Solutions revenue.

03—Filings

Recent SEC Filings

  1. 8-KGE HealthCare Technologies Inc. 8-K Report, Executive Changes (Sep 22, 2026)GE HealthCare Technologies Inc. (GEHC) announced a significant addition to its Board of Directors with the appointment of Pascal Desroches, effective January 4, 2027. Mr. Desroches will also serve on key Board committees, including the Audit Committee and the Talent, Culture, and Compensation Committee. This appointment suggests a strengthening of the Board's oversight and expertise in critical areas. Investors should note that Mr. Desroches' compensation will align with the Company's established program for non-employee directors, and he will enter into a standard indemnification agreement. The filing explicitly states there are no disqualifying arrangements or reportable related-party transactions, indicating a straightforward appointment. The announcement was made via a press release furnished as an exhibit to this 8-K filing.
  2. 8-KGE HealthCare Technologies Inc. 8-K Report, Executive Changes (Aug 18, 2026)GE HealthCare Technologies Inc. announced a significant leadership change with the appointment of William K. Grogan as its new Chief Financial Officer, effective September 14, 2026. Mr. Grogan brings extensive financial leadership experience, most recently serving as CFO of Xylem Inc. and previously as CFO of IDEX Corporation. This appointment marks a transition for the company, with current interim CFO George A. Newcomb returning to his role as Controller and Chief Accounting Officer. Mr. Grogan's compensation package reflects his experience and the incentives designed to attract and retain him, including a substantial base salary, annual bonus targets, and significant long-term equity awards. These awards are structured to align his interests with shareholders, with performance-based and time-based vesting components. The company also provided a cash sign-on payment and an equity award to compensate for forfeited compensation at his previous employer. Investors should monitor the integration of Mr. Grogan into the executive team and his impact on the company's financial strategy and performance.
  3. 8-KGE HealthCare Technologies Inc. 8-K Report, Regulation FD Disclosure (Jul 29, 2026)GE HealthCare Technologies Inc. (GEHC) has filed an 8-K to disclose a strategic reorganization of its business segments, effective Q2 2026. The company has combined its Imaging and Advanced Visualization Solutions businesses into a new 'Advanced Imaging Solutions' (AIS) segment. This move is intended to enhance execution, accelerate innovation, and improve operational efficiencies. Following this change, GE HealthCare will now report under three distinct segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). This new structure aligns with how the Chief Operating Decision Maker assesses performance and allocates resources. The AIS segment will encompass a broad range of diagnostic, interventional, and digital imaging technologies. Key product lines within AIS include Computed Tomography (CT), Magnetic Resonance (MR), Molecular Imaging (MI), solutions for Enterprise Imaging, Women's Health products (X-ray and Ultrasound), and general X-ray systems. The segment also includes offerings for CardioVascular and Interventional Solutions, as well as Surgical Innovations, and Comprehensive Care Ultrasound. The recast historical financial information reflecting this new segment structure is provided as an exhibit to aid investor comparability.
  4. 8-KGE HealthCare Technologies Inc. 8-K Report, Financial Results (Jul 29, 2026)GE HealthCare Technologies Inc. (GEHC) filed an 8-K on July 29, 2026, to announce its second quarter 2026 financial results. This filing primarily serves to furnish the accompanying press release, which details the company's performance for the period. Investors should refer to the press release (Exhibit 99) for specific financial figures, operational updates, and management's commentary on the quarter's results. The 8-K itself does not contain the detailed financial results but rather directs stakeholders to the furnished press release. This is a standard procedure for reporting quarterly earnings, allowing for timely dissemination of information. Key takeaways will be found within the press release, which typically includes metrics such as revenue, earnings per share (EPS), profit margins, segment performance, and forward-looking guidance. Investors should pay close attention to how GEHC performed against analyst expectations, the growth drivers within its key business segments (e.g., Imaging, Ultrasound, Pharmaceutical Diagnostics, and Edison X), and any commentary regarding macroeconomic factors or strategic initiatives that may impact future performance. The company's commentary on its strategic priorities and its ability to execute will be crucial for assessing long-term value.
  5. 8-KGE HealthCare Technologies Inc. 8-K Report, Financial Results (Jul 23, 2026)GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report disclosing preliminary unaudited financial results for the second quarter of 2026, which were also announced via a press release furnished as Exhibit 99. While specific figures for revenue and EPS are not detailed within the 8-K text itself, the furnishing of this preliminary data suggests the company is providing early guidance to the market. Investors should closely review the accompanying press release for the actual Q2 2026 performance metrics. Furthermore, the filing announces a significant leadership change: Chief Financial Officer James K. (Jay) Saccaro will be resigning on August 14, 2026, to pursue opportunities outside the medical technology sector. George Newcomb, currently Controller and Chief Accounting Officer, has been appointed interim CFO, effective August 14, 2026. Mr. Newcomb brings extensive finance experience from GE and GE Capital. The company has initiated a search for a permanent CFO. Investors should monitor the transition and the search process for a new CFO.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.